NASDAQ:ADVM Adverum Biotechnologies (ADVM) Stock Forecast, Price & News $1.50 -0.03 (-1.96%) (As of 03:00 PM ET) Add Compare Share Share Today's Range$1.49▼$1.6350-Day Range$1.52▼$2.2352-Week Range$0.53▼$2.34Volume136,979 shsAverage Volume413,468 shsMarket Capitalization$151.49 millionP/E RatioN/ADividend YieldN/APrice Target$3.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Adverum Biotechnologies MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside138.1% Upside$3.75 Price TargetShort InterestHealthy1.52% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.23Based on 2 Articles This WeekInsider TradingSelling Shares$9,426 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.19) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.58 out of 5 starsMedical Sector128th out of 971 stocksBiological Products, Except Diagnostic Industry14th out of 158 stocks 3.4 Analyst's Opinion Consensus RatingAdverum Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.75, Adverum Biotechnologies has a forecasted upside of 138.1% from its current price of $1.58.Amount of Analyst CoverageAdverum Biotechnologies has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.52% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adverum Biotechnologies has recently increased by 20.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdverum Biotechnologies has received a 77.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Adverum Biotechnologies is -0.78. Previous Next 2.9 News and Social Media Coverage News SentimentAdverum Biotechnologies has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adverum Biotechnologies this week, compared to 0 articles on an average week.Search Interest7 people have searched for ADVM on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows5 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,426.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions70.87% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Adverum Biotechnologies are expected to grow in the coming year, from ($1.19) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adverum Biotechnologies (NASDAQ:ADVM) StockAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Read More ADVM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADVM Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comAdverum Biotechnologies to Participate in Upcoming Investor ConferencesSeptember 19, 2023 | americanbankingnews.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Rises By 5.7%September 29, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 6, 2023 | msn.comTruist Securities Reiterates Adverum Biotechnologies (ADVM) Buy RecommendationSeptember 5, 2023 | finance.yahoo.comAdverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 31, 2023 | msn.comAdverum Biotechnologies (ADVM) Price Target Increased by 13.33% to 4.34August 22, 2023 | finanznachrichten.deAdverum Biotechnologies, Inc.: Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology OfficerAugust 21, 2023 | finance.yahoo.comAdverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology OfficerSeptember 29, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 14, 2023 | finance.yahoo.comAdverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceAugust 12, 2023 | msn.comChardan Capital Upgrades Adverum Biotechnologies (ADVM)August 11, 2023 | msn.comAdverum upgraded at Chardan ahead of key readouts for lead assetAugust 2, 2023 | msn.comAdverum Biotechnologies (ADVM) Price Target Increased by 7.14% to 3.83June 22, 2023 | benzinga.comShort Volatility Alert: Adverum BiotechnologiesJune 12, 2023 | finance.yahoo.comAdverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal CapsidJune 2, 2023 | finance.yahoo.comAdverum Biotechnologies to Participate in the Jefferies Healthcare ConferenceMay 25, 2023 | finance.yahoo.comAdverum Biotechnologies Announces New Executive Leadership RolesMay 18, 2023 | technews.tmcnet.comAdverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual MeetingMay 18, 2023 | finance.yahoo.comAdverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy PlatformMay 18, 2023 | finance.yahoo.comAdverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual MeetingMay 16, 2023 | markets.businessinsider.comAdverum Biotechnologies (ADVM) Receives a Hold from RBC CapitalMay 11, 2023 | finance.yahoo.comAdverum Biotechnologies Reports First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comAdverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare ConferenceMay 2, 2023 | tmcnet.comAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCTMay 2, 2023 | finance.yahoo.comAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMDApril 23, 2023 | finance.yahoo.comAdverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vecApril 21, 2023 | finance.yahoo.comAfter losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gainSee More Headlines Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address ADVM Company Calendar Last Earnings8/10/2023Today9/29/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADVM CUSIPN/A CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees123Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.75 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+151.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,540,000.00 Net MarginsN/A Pretax Margin-3,704.42% Return on Equity-78.63% Return on Assets-46.10% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual Sales$7.50 million Price / Sales20.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / Book0.82Miscellaneous Outstanding Shares100,990,000Free Float95,640,000Market Cap$150.49 million OptionableOptionable Beta0.82 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Laurent Fischer (Age 59)Pres, CEO & Director Comp: $977.23kMs. Linda M. Rubinstein M.A. (Age 56)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $111.89kMr. Kishor Peter Soparkar J.D. (Age 52)Chief Operating Officer Comp: $656.96kMr. John W. Rakow J.D. (Age 66)Sr. VP & Gen. Counsel Comp: $954.24kDr. Setareh Seyedkazemi Pharm.D. (Age 49)Chief Devel. Officer Comp: $834.57kDr. R. Andrew Ramelmeier Ph.D. (Age 61)Chief Technology Officer Dr. Brigit Riley Ph.D. (Age 45)Chief Scientific Officer Ms. Dena HouseSr. VP of HR, Organizational Devel. & LearningMs. Carla FiankanSr. VP of Regulatory AffairsDr. Jim Wang Ph.D.Chief Regulatory OfficerMore ExecutivesKey CompetitorsOrchard TherapeuticsNASDAQ:ORTXX4 PharmaceuticalsNASDAQ:XFORInvivydNASDAQ:IVVDERYTECH PharmaNASDAQ:ERYPFusion PharmaceuticalsNASDAQ:FUSNView All CompetitorsInsiders & InstitutionsSetareh SeyedkazemiSold 6,201 sharesTotal: $9,425.52 ($1.52/share)Osaic Holdings Inc.Sold 30,000 shares on 8/21/2023Ownership: 0.063%Commodore Capital LPBought 5,000,000 shares on 8/15/2023Ownership: 9.902%Worth Venture Partners LLCBought 72,123 shares on 8/15/2023Ownership: 0.367%Cantor Fitzgerald L. P.Bought 20,000 shares on 8/15/2023Ownership: 0.161%View All Insider TransactionsView All Institutional Transactions ADVM Stock - Frequently Asked Questions Should I buy or sell Adverum Biotechnologies stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ADVM shares. View ADVM analyst ratings or view top-rated stocks. What is Adverum Biotechnologies' stock price forecast for 2023? 4 brokerages have issued 1 year target prices for Adverum Biotechnologies' shares. Their ADVM share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $3.75 in the next year. This suggests a possible upside of 151.7% from the stock's current price. View analysts price targets for ADVM or view top-rated stocks among Wall Street analysts. How have ADVM shares performed in 2023? Adverum Biotechnologies' stock was trading at $0.5795 at the beginning of the year. Since then, ADVM shares have increased by 157.1% and is now trading at $1.4901. View the best growth stocks for 2023 here. Are investors shorting Adverum Biotechnologies? Adverum Biotechnologies saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,340,000 shares, an increase of 20.7% from the August 31st total of 1,110,000 shares. Based on an average daily trading volume, of 438,300 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.5% of the shares of the company are short sold. View Adverum Biotechnologies' Short Interest. When is Adverum Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ADVM earnings forecast. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) announced its earnings results on Thursday, August, 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.01. What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO? 3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA). What is Adverum Biotechnologies' stock symbol? Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM." How do I buy shares of Adverum Biotechnologies? Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adverum Biotechnologies' stock price today? One share of ADVM stock can currently be purchased for approximately $1.49. How much money does Adverum Biotechnologies make? Adverum Biotechnologies (NASDAQ:ADVM) has a market capitalization of $150.49 million and generates $7.50 million in revenue each year. The biotechnology company earns $-154,540,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. How many employees does Adverum Biotechnologies have? The company employs 123 workers across the globe. How can I contact Adverum Biotechnologies? Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.adverum.com. The biotechnology company can be reached via phone at (650) 656-9323, via email at mlacy@adverum.com, or via fax at 650-329-8151. This page (NASDAQ:ADVM) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.